

# Lukas Flatz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2242989/publications.pdf>

Version: 2024-02-01

21  
papers

980  
citations

687363

13  
h-index

713466

21  
g-index

23  
all docs

23  
docs citations

23  
times ranked

1693  
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2019, 5, 1043.	7.1	266
2	Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors. <i>European Journal of Cancer</i> , 2019, 107, 8-14.	2.8	127
3	Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer. <i>Onc Immunology</i> , 2016, 5, e1231292.	4.6	89
4	CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ T Cells. <i>Immunity</i> , 2020, 53, 805-823.e15.	14.3	79
5	Severe Coronavirus Disease 2019 (COVID-19) is Associated With Elevated Serum Immunoglobulin (Ig) A and Antiphospholipid IgA Antibodies. <i>Clinical Infectious Diseases</i> , 2021, 73, e2869-e2874.	5.8	69
6	BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 854-861.	1.2	64
7	Epidemiology of cutaneous melanoma and keratinocyte cancer in white populations 1943-2036. <i>European Journal of Cancer</i> , 2021, 152, 18-25.	2.8	49
8	A novel proangiogenic B cell subset is increased in cancer and chronic inflammation. <i>Science Advances</i> , 2020, 6, eaaz3559.	10.3	36
9	Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment. <i>Journal of Clinical Oncology</i> , 2022, 40, 3741-3749.	1.6	33
10	Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma. <i>EBioMedicine</i> , 2020, 59, 102962.	6.1	31
11	Local tumor microbial signatures and response to checkpoint blockade in non-small cell lung cancer. <i>Onc Immunology</i> , 2021, 10, 1988403.	4.6	28
12	Adoptive T Cell Therapy Targeting Different Gene Products Reveals Diverse and Context-Dependent Immune Evasion in Melanoma. <i>Immunity</i> , 2020, 53, 564-580.e9.	14.3	27
13	Cutaneous melanoma attributable to UVR exposure in Denmark and Germany. <i>European Journal of Cancer</i> , 2021, 159, 98-104.	2.8	11
14	Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry. <i>Cancers</i> , 2021, 13, 6141.	3.7	11
15	Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 647-656.	2.5	6
16	Keratinocyte differentiation antigen-specific T cells in immune checkpoint inhibitor-treated NSCLC patients are associated with improved survival. <i>Onc Immunology</i> , 2021, 10, 2006893.	4.6	4
17	Prognostic role of gamma-glutamyl transferase in metastatic melanoma patients treated with immune checkpoint inhibitors. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1089-1099.	4.2	3
18	Fingolimod and tumor-infiltrating lymphocytes in checkpoint-inhibitor treated cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 563-568.	4.2	3

#	ARTICLE	IF	CITATIONS
19	Recombinant lymphocytic choriomeningitis virus-based vaccine vector protects type I interferon receptor deficient mice from viral challenge. <i>Vaccine</i> , 2021, 39, 1257-1264.	3.8	2
20	Genome-Wide Association Study Suggests the Variant rs7551288*A within the DHCR24 Gene Is Associated with Poor Overall Survival in Melanoma Patients. <i>Cancers</i> , 2022, 14, 2410.	3.7	2
21	Abstract LB058: Imaging of CD8+ cytotoxic T-cells by Zr-89-Df-IAB22M2C PET/MRI: First clinical experience in patients with metastatic cancer. <i>Cancer Research</i> , 2022, 82, LB058-LB058.	0.9	0